SRR12202430
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.470
- PANCREAS_BETA_CELLS+0.400
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.250
- SPERMATOGENESIS+0.240
- ANDROGEN_RESPONSE+0.200
- PEROXISOME+0.200
- BILE_ACID_METABOLISM+0.190
- CHOLESTEROL_HOMEOSTASIS+0.190
- FATTY_ACID_METABOLISM+0.190
Top 10 suppressed
- ANGIOGENESIS-0.420
- INTERFERON_ALPHA_RESPONSE-0.390
- WNT_BETA_CATENIN_SIGNALING-0.370
- ALLOGRAFT_REJECTION-0.360
- INTERFERON_GAMMA_RESPONSE-0.360
- HEDGEHOG_SIGNALING-0.330
- P53_PATHWAY-0.330
- APICAL_JUNCTION-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- IL6_JAK_STAT3_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R150 | — | — | 0.905 |
| 2 | R391 | — | — | 0.897 |
| 3 | R288 | — | — | 0.876 |
| 4 | SRR17866837 | — | — | 0.872 |
| 5 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.854 |
| 6 | DRR168591 | — | — | 0.852 |
| 7 | R356 | — | — | 0.850 |
| 8 | DRR168601 | — | — | 0.848 |
| 9 | SRR6013568 | — | cohortA2 | 0.843 |
| 10 | SRR1797279 | — | cohortSC | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |